Fax: (858) 822-5568
Predictors of competing mortality in early breast cancer
Article first published online: 24 AUG 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 23, pages 5365–5373, 1 December 2010
How to Cite
Mell, L. K., Jeong, J.-H., Nichols, M. A., Polite, B. N., Weichselbaum, R. R. and Chmura, S. J. (2010), Predictors of competing mortality in early breast cancer. Cancer, 116: 5365–5373. doi: 10.1002/cncr.25370
- Issue published online: 23 NOV 2010
- Article first published online: 24 AUG 2010
- Manuscript Accepted: 1 FEB 2010
- Manuscript Revised: 6 JAN 2010
- Manuscript Received: 6 NOV 2009
- breast cancer;
- competing mortality;
- noncancer mortality;
- competing risks;
- racial disparities
Death in the absence of disease recurrence (competing mortality) is an important determinant of disease-free survival (DFS) in early breast cancer. The authors sought to identify predictors of this event using competing risks modeling.
A cohort study was made of 1231 consecutive women with stage I to II invasive breast cancer diagnosed between 1986 and 2004, treated with breast conservation therapy. Median follow-up was 82 months. The authors used a parametric competing risks regression model to analyze factors associated with the cumulative incidence of competing mortality. They generated a risk score from the model coefficient estimates and stratified patients according to low and high risk score for analysis.
Ten-year DFS was 69.7% (95% confidence interval [CI], 66.2%-72.9%). The 10-year cumulative incidence of locoregional recurrence (LRR) was 4.4% (95% CI, 3.0%-5.8%), distant recurrence was 7.1% (95% CI, 5.4%-8.9%), and competing mortality was 18.7% (95% CI, 15.9%-21.6%). On multivariate analysis, competing mortality was associated with increasing age (hazard ratio [HR], 1.83 per 10 years; 95% CI, 1.58-2.12), black race (HR, 1.71; 95% CI, 1.17-2.51), and comorbid disease (HR, 1.93, 95% CI, 1.40-2.65). Ten-year cumulative incidences of competing mortality, locoregional recurrence, and distant recurrence for patients at low (n = 638) versus high (n = 593) risk of competing mortality were 7.2% versus 30.6% (P < .001), 4.4% versus 4.4% (P = .97), and 8.6% versus 5.6% (P = .12), respectively.
Competing mortality is an important event influencing 10-year DFS in early breast cancer and is associated with increasing age, black race, and comorbid disease. Stratifying patients according to competing mortality risk may be useful in designing clinical trials. Cancer 2010. © 2010 American Cancer Society.